Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial - Top-Institutions - MDSpire

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial

  • By

  • Sebastian Wolf

  • Youxin Chen

  • Xiaorong Li

  • Masahiko Shimura

  • Taiji Sakamoto

  • Charles C. Wykoff

  • Andres Emanuelli

  • Hani Salehi-Had

  • Kang Yan

  • Lidija Kovacic

  • Yongsoo Kim

  • June 1, 2026

  • 0 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    CONDOR study
    CONDOR study

    N/A, N/A

    Key Differentiators

    • Ophthalmology

  • #2

    National Eye Institute
    National Eye Institute

    Bethesda, MD

    Key Differentiators

    • Ophthalmology

  • #3

    Diabetic Retinopathy Clinical Research Network
    Diabetic Retinopathy Clinical Research Network

    N/A, N/A

    Key Differentiators

    • Ophthalmology

Original Source(s)

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial

  • by Sebastian Wolf, Youxin Chen, Xiaorong Li, Masahiko Shimura, Taiji Sakamoto, Charles C. Wykoff, Andres Emanuelli, Hani Salehi-Had, Kang Yan, Lidija Kovacic, Yongsoo Kim

  • June 1, 2026

Related Content

Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

At Retina World Congress, Patricio G. Schlottmann, MD, discussed investigational widefield OCTA platforms made by Chinese company TowardPi Medical.

Comparative study of the therapeutic effects of different medications on DM-associated dry eye syndrome after vitrectomy

AACE 2026: Will AI replace endocrinologists?

The same technology drawing patients away from clinic may also improve the patient-physician relationship.